BillionToOne, Inc. BLLN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies

Guardant HealthGH

——

Tango TherapeuticsTNGX

——

ImmunityBio, Inc.IBRX

——

Crinetics PharmaceuticalsCRNX

——

Other financials

Income statement

See full

Revenue$108.4M+83.8%

Gross profit$79.1M+108%

Operating income$17.8M+870%

Net income$18.0M+551%

EPS (diluted)$0.34+187%

Balance sheet

See full

Cash & equivalents$537.5M+181%

Total debt$144.2M—

Total equity$505.6M+300%

Total assets$700.7M—

Cash flow

See full

Operating cash flow$15.4M+488%

CapEx$4.5M+90.5%

Free cash flow$11.0M+3,842%

Valuation

See full

Market cap$4.84B—

Profitability

See full

Gross margin70.4%—

Operating margin-96.9%—

Net margin8.4%—

FCF margin-83.4%—

Returns & leverage

See full

Debt / equity0.3×—

Current ratio10.9×—

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BillionToOne, Inc. 's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?: BillionToOne, Inc. (BLLN) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $614.21M in Q1 2026.